Astellas/UMN Complete Inoculations In Phase III Seasonal Influenza Vaccine Study
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharmaceuticals and UMN Pharma have completed the inoculation of all subjects in a Phase III trial for ASP7374, a cell culture seasonal influenza vaccine, the companies announced Dec. 11.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.